{"url_path":"/sec/tsha/8-k/2026-06-25/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001193125-26-282855-index.html","accession_number":"0001193125-26-282855","cik":"0001806310","ticker":"TSHA","issuer_name":"Taysha Gene Therapies, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001193125-26-282855-index.html","primary_entity_key":"0001806310","primary_entity_name":"Taysha Gene Therapies, Inc."},"word_count":134,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\n  \nExhibit Description\n\n1.1\n  \n[Underwriting Agreement by and between Taysha Gene Therapies, Inc. and Jefferies LLC and Goldman Sachs & Co. LLC, dated June 24, 2026.](d121397dex11.htm)\n\n4.1\n  \n[Form of Pre-Funded Warrant.](d121397dex41.htm)\n\n5.1\n  \n[Opinion of Cooley LLP.](d121397dex51.htm)\n\n23.1\n  \n[Consent of Cooley LLP (included in Exhibit 5.1).](d121397dex51.htm)\n\n99.1\n  \n[Press Release, dated June 24, 2026.](d121397dex991.htm)\n\n99.2\n  \n[Press Release, dated June 24, 2026.](d121397dex992.htm)\n\n104\n  \nCover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nTaysha Gene Therapies, Inc.\n\n \n\n \nBy:\n \n\n/s/ Kamran Alam\n\nDate: June 25, 2026\n \n\n \n\n \nKamran Alam\n\n \n\n \n\n \nChief Financial Officer"}